134 related articles for article (PubMed ID: 35822121)
1. A quality improvement project reduces time spent at an inflammatory bowel disease infusion center with accelerated infliximab infusion protocol.
Ong WC; Lim MS; Chan E; Lim TCT; Lim TG; Chan W
JGH Open; 2022 Jul; 6(7):470-476. PubMed ID: 35822121
[TBL] [Abstract][Full Text] [Related]
2. Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness.
McConnell J; Parvulescu-Codrea S; Behm B; Hill B; Dunkle E; Finke K; Snyder K; Tuskey A; Cox D; Woodward B
World J Gastrointest Pharmacol Ther; 2012 Oct; 3(5):74-82. PubMed ID: 23515325
[TBL] [Abstract][Full Text] [Related]
3. Safety, satisfaction and cost savings of accelerated infusions of standard and intensified-dose infliximab for inflammatory bowel disease.
Crane H; Wu N; Chan P; Nguyen P; Williams AJ; Ng W; Connor SJ
Intern Med J; 2022 Dec; 52(12):2143-2149. PubMed ID: 34405958
[TBL] [Abstract][Full Text] [Related]
4. Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study.
Abushamma S; Walker T; Garza K; Chen L; Nix D; Chen CH
Crohns Colitis 360; 2023 Jul; 5(3):otad022. PubMed ID: 37288326
[TBL] [Abstract][Full Text] [Related]
5. Safety and cost benefit of an accelerated infliximab infusion protocol in the treatment of ambulatory patients with inflammatory bowel diseases.
Saxena P; Chen G; Jideh B; Collins G; Leong RW
Expert Opin Biol Ther; 2014 Mar; 14(3):277-82. PubMed ID: 24359522
[TBL] [Abstract][Full Text] [Related]
6. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
[TBL] [Abstract][Full Text] [Related]
7. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?
Bhat S; Sharma D; Doherty P; Tham TC; Caddy GR
Inflamm Bowel Dis; 2010 Nov; 16(11):1922-5. PubMed ID: 20848465
[TBL] [Abstract][Full Text] [Related]
8. Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients' Satisfaction and Cost Analysis. A Cohort Study in IBD Patients.
Mazzuoli S; Tricarico D; Demma F; Furneri G; Guglielmi FW
PLoS One; 2016; 11(11):e0166443. PubMed ID: 27851772
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study.
Viola A; Costantino G; Privitera AC; Bossa F; Lauria A; Grossi L; Principi MB; Della Valle N; Cappello M
World J Gastrointest Pharmacol Ther; 2017 May; 8(2):131-136. PubMed ID: 28533923
[TBL] [Abstract][Full Text] [Related]
10. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
[TBL] [Abstract][Full Text] [Related]
11. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
Null K; Kumar V; Lissoos T; Luo M
J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
[TBL] [Abstract][Full Text] [Related]
12. Increasing Biosimilar Utilization at a Pediatric Inflammatory Bowel Disease Center and Associated Cost Savings: Show Me the Money.
Morris GA; McNicol M; Boyle B; Donegan A; Dotson J; Michel HK; Maltz RM
Inflamm Bowel Dis; 2022 Mar; 28(4):531-538. PubMed ID: 34037215
[TBL] [Abstract][Full Text] [Related]
13. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease.
Qazi T; Shah B; El-Dib M; Farraye FA
Dig Dis Sci; 2016 Feb; 61(2):589-96. PubMed ID: 26441281
[TBL] [Abstract][Full Text] [Related]
14. Decreasing Door-to-Door Times for Infliximab Infusions in a Children's Hospital Observation Unit.
Sandberg KC; Lucien JN; Stoll D; Yanney E; Mezoff A
Pediatr Qual Saf; 2019; 4(1):e131. PubMed ID: 30937413
[TBL] [Abstract][Full Text] [Related]
15. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
[TBL] [Abstract][Full Text] [Related]
16. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
[TBL] [Abstract][Full Text] [Related]
17. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
[TBL] [Abstract][Full Text] [Related]
18. Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease.
Babouri A; Buisson A; Bigard MA; Peyrin-Biroulet L
J Crohns Colitis; 2013 Mar; 7(2):129-33. PubMed ID: 22472090
[TBL] [Abstract][Full Text] [Related]
19. Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening.
Ben-Shatach Z; Ziv-Baran T; Fudim E; Yavzori M; Picard O; Levartovsky A; Selinger L; Weiss B; Kopylov U; Eliakim R; Ungar B
Therap Adv Gastroenterol; 2022; 15():17562848221083395. PubMed ID: 35646158
[TBL] [Abstract][Full Text] [Related]
20. A home infliximab infusion program.
Condino AA; Fidanza S; Hoffenberg EJ
J Pediatr Gastroenterol Nutr; 2005 Jan; 40(1):67-9. PubMed ID: 15625429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]